Giacomo Corleone retweeted
#Myeloma Paper of the Day: Nuclear respiratory factor 1 promotes cell survival in myeloma under proteasome inhibition & antisense oligos targeting NRF1 enhancer alone or combined with BTZ, significantly decrease tumor burden and improve survival: pubmed.ncbi.nlm.nih.gov/4092…. #mmsm
Thrilled and excited to share with you our new team effort with a new study just published. ashpublications.org/blood/ar…
This strategy challenges the "undruggable" transcription factor paradigm by offering a potentially highly effective targeted intervention approach.
Kudos to all the authors for their incredible work, our institution @IREISGufficiale, the funders @AIRC_it, and all the patients who fundamentally contributed to this research #multiplemyeloma
Excited to share our latest research on enhancer activity driving B-cell acute lymphoblastic leukemia. Check out how we unravel novel molecular mechanisms sustaining this disease! #LeukemiaResearch #CancerBiology
Just Published! 🪸
Enhancer engagement sustains oncogenic transformation and progression of B-cell precursor #acutelymphoblasticleukemia
Look here👇
jeccr.biomedcentral.com/arti…
#CRISPRCas9
#EnhancerReprogramming
if you're interested in learning about Multiple Myeloma and epigenetics, join me at poster 851 at #EHA2024. Let's discuss gene regulation and its impact on myeloma. See you there! #myeloma #gene_regulation
Giacomo Corleone retweeted
The last month was the second warmest December ever, with 2°C average above the reference period (1991-2020) in #Italy (Data source ERA5).
Dicembre 2023 in #Italia ha registrato un aumento di temperatura di quasi 2 gradi di media, con punte di 5 sulle #Alpi. #ClimateEmergency
Giacomo Corleone retweeted
Super excited to see my first graphical #abstract on the #cover of @JTOonline!
The latest review by @stescalera & @MaugeriSacca about the molecular functions of the KEAP1-NRF2 pathway, its role in #lungcancer and how KEAP1/NFE2L2 mutations reduce the efficacy of treatments💊 – at Rome, Lazio
